SENSEX NIFTY

Trastuzumab

Apr 26, 2016 at 20:00 | Source: PTI
Biotechnology firm Biocon today said its product portfolio will not be affected by an order of the Delhi High Court that prevented the company from calling its breast cancer medicine Trastuzumab as a biosimilar of Roche's Herceptin.
Apr 05, 2016 at 10:41 | Source: Moneycontrol.com
It believes that Biocon's (and its partner Mylan) four potential product filings each in the US and EU would add credibility to its pipeline and bring market recognition. Emerging market monetisation is under way, but the US and EU opportunities will take at least two years, according to report.
Sep 15, 2015 at 16:45 | Source: PTI
GBR 1302, a bi-specific monoclonal antibody, is an artificial protein that is composed of fragments of two different monoclonal antibodies and consequently binds two different types of antigens.
Feb 07, 2014 at 22:27 | Source: CNBC-TV18
The Delhi High Court (HC) has thrown a wrench into plans of Biocon and Mylan to market a breast cancer drug that goes by the scientific name Trastuzumab.
Feb 04, 2014 at 09:59 | Source: PTI
The company's subsidiary Mylan Pharmaceuticals Pvt Ltd has launched the world's first trastuzumab biosimilar, which will be marketed by Mylan under the brand name Hertraz Herceptin, a company statement said.
Jan 18, 2014 at 16:21 | Source: Reuters
Bangalore-based Biocon jointly developed biosimilar trastuzumab, which received the Indian drug regulator's marketing approval in November, with US-based Mylan Inc.
Nov 26, 2013 at 14:42 | Source: Moneycontrol.com
Biocon has received marketing authorization from the Drugs Controller General of India for its Biosimilar Trastuzumab being developed jointly with Mylan, for treatment of Her 2+ metastatic breast cancer.
Messages on Trastuzumab »

Wire News

Platinum Member

715 Followers

News Now  

The Delhi High Court today told Swiss pharma major Roche that it "cannot hang on to" breast cancer drug Trastuzumab, innovated by it, for the rest of its life after having enjoyed the fruits of its patent.

8.38 PM Feb 22nd

andyin

New Member

6 Followers

Biocon  

In Sept 2017 it will be Trastuzumab with FDA. May/June is 2017 is expected for EMA review to complete for both molecules and glargine in Sept/oct 2017

8.13 PM Feb 16th

News Flash

Platinum Member

1380 Followers

Just Posted  

Biocon On CNBC-TV18 : Announced Trastuzumab Biosimilar Filing Acceptance By US FDA

11.00 AM Jan 25th

News Flash

Platinum Member

1380 Followers

Just Posted  

Biocon On CNBC-TV18 : Announced Trastuzumab Biosimilar Filing Acceptance By US FDA

10.45 AM Jan 25th

BSE/NSE Announcer

Platinum Member

21390 Followers

Biocon  

Biocon Ltd has informed BSE regarding a Press Release dated January 11, 2017, titled "U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocons Proposed Biosimilar Trastuzumab".

6.32 PM Jan 11th

savera_patn
a

Platinum Member

40 Followers

Biocon  

Bond 007 !!! Glargine EU approval by end of 2017 is my estimated timeline , Peg-filgrastim July 2017 then Trastuzumab by December 17 ....

11.27 AM Jan 10th

dhruvfun

New Member

3 Followers

Biocon  

i can`t believe how people are not able to understand what biocon is !! biocon is a world class biopharma firm, that has world class talent pool of scientists!! its trastuzumab biosimilar is showing much better results than herceptin which generates 40,000 crores alone in revenue for roche!! it

10.07 AM Jan 5th

rjstocks99

New Member

2 Followers

Biocon  

Published study results showed an overall response rate of 69.6 per cent for MYL-1401O compared to 64 per cent for branded trastuzumab

5.41 PM Dec 28th 2016

rjstocks99

New Member

2 Followers

Biocon  

Hope S. Rugo, professor of medicine at the University of California, San Francisco, said: This study was the last major step of a multiple-phased program to demonstrate that proposed biosimilar trastuzumab meets the criteria for equivalence in comparison to branded trastuzumab.

5.40 PM Dec 28th 2016

rjstocks99

New Member

2 Followers

Biocon  

The results confirm the efficacy, safety and immunogenicity of MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon, in comparison to branded trastuzumab, according to a company statement

5.33 PM Dec 28th 2016

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.